BiotechTubeBiotechTube
Home/Pipeline/BIIB122/DNL151

BIIB122/DNL151

Parkinson's disease

Phase 3Active (LIGHTHOUSE study)

Key Facts

Indication
Parkinson's disease
Phase
Phase 3
Status
Active (LIGHTHOUSE study)
Company
Denali Therapeutics

About Denali Therapeutics

Denali Therapeutics is a public biotech company focused on discovering, developing, and delivering medicines for serious diseases, with a particular emphasis on crossing biological barriers to reach the brain. The company's proprietary TransportVehicle™ platform is central to its strategy, aiming to transform treatment for neurodegenerative and lysosomal storage disorders. Denali has built a diverse clinical-stage pipeline through both internal R&D and strategic partnerships, positioning itself at the forefront of next-generation CNS therapeutics. The company is headquartered in South San Francisco, California, and trades on the NASDAQ under the ticker DNLI.

View full company profile

Therapeutic Areas

Neurodegenerative DiseasesLysosomal Storage DisordersCentral Nervous System (CNS)

Other Parkinson's disease Drugs

DrugCompanyPhase
ABBV-951AbbViePhase 3
UCB0107UCBPhase 1
StalevoOrion CorporationApproved
Comtan/ComtessOrion CorporationApproved
CHRONOS-PD PlatformGrifolsResearch
GT-001 (Gene Therapy)Sumitomo PharmaPhase 1/2
CREXONT (Carbidopa/Levodopa)Amneal PharmaceuticalsApproved
ABBV-0805BioArctic ABPhase 1
BAN1202BioArctic ABPreclinical
ARV-102ArvinasPhase 1
AAV-GADMeiraGTxPreclinical/Phase 1
Not SpecifiedMinerva NeurosciencesClinical Stage